

2444-105  
MC: smt

Office Of Initial Patent Examination's  
Customer Service Center

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
XU et al. )  
Serial No. 09/914,046 ) Examiner: To be assigned  
Filed: October 1, 2001 ) Group Art Unit: 1642  
For: ANTIBODY FRAGMENT-TARGETED  
IMMUNOLIPOSOMES FOR SYSTEMIC  
GENE DELIVERY )

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants are in receipt of the Official Filing Receipt dated April 11, 2002 and have noted the following errors in the Applicants name and state of residence.

Please change:

"Liang Xu, Arlington, CHINA" to --Liang Xu, Arlington, VA--;

"Cheng-Cheng Huang, Arlington, CHINA" to --Cheng-Cheng Huang, Arlington VA;


"William Alexander, Rockville, MD" to --William Alexander, Rockville, MD--;

"WenHua Tang, Arlington, CHINA" to --WenHua Tang, Arlington, VA.--

The changes are marked in red on the accompanying copy.

Respectfully submitted,

By:



Martha Cassidy  
Attorney for Applicants  
Registration No.: 44,066  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K, N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040

2444-105.fr



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/914,046	10/01/2001	1642	1007	2444-105-1	9	68	5

CONFIRMATION NO. 8537

## REPLACEMENT FILING RECEIPT



\*OC000000007845651\*

6449


ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
1425 K STREET, N.W.  
SUITE 800  
WASHINGTON, DC 20005

Date Mailed: 04/11/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Liang Xu, Arlington, CHINA, [VA]  
Cheng-Cheng Huang, Arlington, CHINA, [VA]  
[William] William Alexander, Rockville, MD, [VA]  
WenHua Tang, Arlington, CHINA, [VA]  
Esther H. Chang, Chevy Chase, MD;



## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US00/04392 02/22/2000  
WHICH CLAIMS BENEFIT OF 60/121,133 02/22/1999

## Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29, 2000


Non-Publication Request: No

Early Publication Request: No

\* SMALL ENTITY \*\*

## Title

Antibody fragment-targeted immunoliposomes for systemic gene delivery





## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/914,046	10/01/2001	1644	1007	2444-105-I	9	68	5

CONFIRMATION NO. 8537

## CORRECTED FILING RECEIPT



\*OC000000014298830\*

6449  
 ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
 1425 K STREET, N.W.  
 SUITE 800  
 WASHINGTON, DC 20005

Date Mailed: 11/05/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Liang Xu, Arlington, VA;  
 Cheng-Cheng Huang, Arlington, VA;  
 William Alexander, Rockville, MD;  
 WenHua Tang, Arlington, VA;  
 Esther H. Chang, Chevy Chase, MD;

**Power of Attorney:** The patent practitioners associated with Customer Number **6449**.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US00/04392 02/22/2000  
 which claims benefit of 60/121,133 02/22/1999

## Foreign Applications

If Required, Foreign Filing License Granted: 11/04/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US09/914,046**

**Projected Publication Date:** None, application is not eligible for pre-grant publication

**Non-Publication Request:** No

**Early Publication Request:** No

**\*\* SMALL ENTITY \*\***

**Title**

Antibody fragment-targeted immunoliposomes for systemic gene delivery

**Preliminary Class**

424

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).